Bruce Fahr

Deep experience in medicinal chemistry and structure-based and fragment-based drug design, using compound design to solve pharmaceutical problems. Inventor of countless structural modifications that improved PK, avoided off-targets, improved potency, efficacy, safety. Managing role in an oncology hit-to-lead group taking projects from inception through in vivo proof-of-concept, with simultaneous oversight of multiple targets. Several target classes and disease areas including transcription factors, proteases (inflammation, Alzheimers), kinases (oncology, inflammation), protein homeostasis, epigenetic targets, binding proteins. Experience in programs from HTS through development candidate (DC) nomination. Lead chemist on multiple targets including kinases, proteases, and transcription factors. Invented multiple proprietary scaffolds, many of which became the lead series for their projects. Optimization of oral exposure in multiple chemical series. Coordination of hit-to-lead chemistry with other departments including biochemistry, cell biology, DMPK and pharmacology. Direct supervision of several BS/MS level chemists, and indirect supervision of multiple MS/PhD chemists in hit-to-lead group. Resource management of internal FTEs as well as external FTEs at multiple overseas CRO sites. Teams up to 14 chemists. Drove programs to definitive go/no go decisions on multiple targets. Specialties: Expert at designing molecules with structural novelty, selectivity, high potency, bioavailability, and appropriate pharmaceutical/DMPK/Tox properties.